ClinicalTrials.gg
CompletedNCT02121847IMPACTUpdated Apr 18, 2019Results posted

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

A Phase 4 interventional study of cyclosporine 0.05% ophthalmic emulsion and carboxymethylcellulose-based lubricant eye drops in Dry Eye Syndromes, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Enrollment
26th of 41
40 · median 51
Started
2014
with 1 other
Phase 4
23 of 45
3 open now
Registered
15th of 45
by date
Lead sponsor
4 of 45
Allergan

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 26th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2014, is one of 23 in phase 4, and was the 15th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of dry eye in both eyes
  • Willing to use eye drops for dry eye symptoms

Exclusion criteria

Exclusion Criteria:

  • Anticipate wearing contact lenses during the study
  • Laser-assisted in situ keratomileusis (LASIK) surgery within the past 12 months
  • Any ocular and/or lid surgeries within the past 6 months
  • Cataract surgery in either eye
  • Current or anticipated use of temporary punctal plugs during the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    cyclosporine 0.05% ophthalmic emulsion

    Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.

    Drug: cyclosporine 0.05% ophthalmic emulsion · Drug: carboxymethylcellulose-based lubricant eye drops

Interventions

  • Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.

    Also known as: Restasis®

  • Drugcarboxymethylcellulose-based lubricant eye drops

    Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.

    Also known as: Refresh OPTIVE® Advanced

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye

    Total corneal staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Corneal Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).

    Time frame: Baseline, Month 6

  2. Change From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye

    Total conjunctival staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).

    Time frame: Baseline, Month 6

  3. Change From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye

    Total corneal staining with lissamine green is measured in the worse eye utilizing the Ora CalibraTM Corneal Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).

    Time frame: Baseline, Month 6

  4. Change From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye

    Total conjunctival staining with lissamine is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).

    Time frame: Baseline, Month 6

  5. Change From Baseline in Reading on the Ocular Surface Disease Index (OSDI)

    The OSDI consists of 12 questions measuring the presence of ocular symptoms. The reading question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The reading score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

    Time frame: Baseline, Month 6

  6. Change From Baseline in Driving at Night on the OSDI

    The OSDI consists of 12 questions measuring the presence of ocular symptoms. The driving at night question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The driving at night score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

    Time frame: Baseline, Month 6

  7. Change From Baseline in Working With a Computer or Bank Machine on the OSDI

    The OSDI consists of 12 questions measuring the presence of ocular symptoms. The working with a computer or bank machine question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The working with a computer or bank machine score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

    Time frame: Baseline, Month 6

  8. Change From Baseline in Watching TV on the OSDI

    The OSDI consists of 12 questions measuring the presence of ocular symptoms. The watching TV question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The watching TV score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

    Time frame: Baseline, Month 6

  9. Change From Baseline in Reading Rate

    Reading speed is assessed as the number of words read correctly in 2 minutes.

    Time frame: Baseline, Month 6

  10. Change From Baseline in Words Read Incorrectly

    The numbers of words read incorrectly are counted in 2 minutes. A positive change from baseline indicates a worsening, and a negative change from baseline indicates an improvement.

    Time frame: Baseline, Month 6

  11. Change From Baseline in Font Size

    The minimum font (letter) size read correctly is assessed. Smaller font size indicates better ability. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Change From Baseline in OSDI

    The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

    Time frame: Baseline, Month 6

  2. Change From Baseline in Ocular Discomfort on a 4-point Scale

    Ocular discomfort is assessed on a 4-point scale where 0=no discomfort and 3=most discomfort. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.

    Time frame: Baseline, Month 6

  3. Change From Baseline in Tear Film Break-up Time in the Worse Eye

    TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement and a negative number change from baseline indicates a worsening.

    Time frame: Baseline, Month 6

  4. Change From Baseline in the Interblink Interval in the Worse Eye

    The interblink interval measures the time (seconds) between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.

    Time frame: Baseline, Month 6

  5. Change From Baseline in Conjunctival Redness in the Worse Eye

    Conjunctival redness is scored in the worse eye on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.

    Time frame: Baseline, Month 6

07

Results

Posted Apr 25, 2016

Participant flow

Participant flow — Overall Study
MilestoneCyclosporine 0.05% Ophthalmic Emulsion
Started40
Completed37
Not completed3
Withdrew: Administrative reasons1
Withdrew: Adverse event2

Outcome measures

PrimaryChange From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye

Total corneal staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Corneal Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline7.29 ± 1.409
Change from Baseline at Month 6 (N=37)-1.96 ± 1.677
PrimaryChange From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye

Total conjunctival staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline4.68 ± 1.035
Change from Baseline at Month 6 (N=37)0.11 ± 1.162
PrimaryChange From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye

Total corneal staining with lissamine green is measured in the worse eye utilizing the Ora CalibraTM Corneal Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline4.43 ± 1.389
Change from Baseline at Month 6 (N=37)-0.93 ± 1.439
PrimaryChange From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye

Total conjunctival staining with lissamine is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline4.21 ± 1.255
Change from Baseline at Month 6 (N=37)0.30 ± 1.356
PrimaryChange From Baseline in Reading on the Ocular Surface Disease Index (OSDI)

The OSDI consists of 12 questions measuring the presence of ocular symptoms. The reading question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The reading score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Reading on the Ocular Surface Disease Index (OSDI)
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline1.4 ± 1.11
Change from Baseline at Month 6 (N=36)-0.7 ± 1.07
PrimaryChange From Baseline in Driving at Night on the OSDI

The OSDI consists of 12 questions measuring the presence of ocular symptoms. The driving at night question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The driving at night score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Driving at Night on the OSDI
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline2.3 ± 1.46
Change from Baseline at Month 6 (N=28)-0.5 ± 1.32
PrimaryChange From Baseline in Working With a Computer or Bank Machine on the OSDI

The OSDI consists of 12 questions measuring the presence of ocular symptoms. The working with a computer or bank machine question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The working with a computer or bank machine score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Working With a Computer or Bank Machine on the OSDI
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline2.2 ± 1.10
Change from Baseline at Month 6 (N=34)-1.0 ± 1.06
PrimaryChange From Baseline in Watching TV on the OSDI

The OSDI consists of 12 questions measuring the presence of ocular symptoms. The watching TV question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The watching TV score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Watching TV on the OSDI
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline1.7 ± 1.04
Change from Baseline at Month 6 (N=32)-0.8 ± 1.04
PrimaryChange From Baseline in Reading Rate

Reading speed is assessed as the number of words read correctly in 2 minutes.

Time frame:
Baseline, Month 6
Reported as:
Mean · Words/Minute
Change From Baseline in Reading Rate
Words/MinuteCyclosporine 0.05% Ophthalmic Emulsion
Baseline105.2 ± 17.11
Change from Baseline at Month 6 (N=37)3.5 ± 11.69
PrimaryChange From Baseline in Words Read Incorrectly

The numbers of words read incorrectly are counted in 2 minutes. A positive change from baseline indicates a worsening, and a negative change from baseline indicates an improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · Words
Change From Baseline in Words Read Incorrectly
WordsCyclosporine 0.05% Ophthalmic Emulsion
Baseline0.4 ± 0.64
Change from Baseline at Month 6 (N=37)0.2 ± 0.90
PrimaryChange From Baseline in Font Size

The minimum font (letter) size read correctly is assessed. Smaller font size indicates better ability. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Size
Change From Baseline in Font Size
SizeCyclosporine 0.05% Ophthalmic Emulsion
Baseline12.0 ± 0.00
Change from Baseline at Month 6 (N=37)-0.2 ± 0.75
SecondaryChange From Baseline in OSDI

The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in OSDI
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline47.0 ± 16.97
Change from Baseline at Month 6 (N=37)-19.7 ± 14.43
SecondaryChange From Baseline in Ocular Discomfort on a 4-point Scale

Ocular discomfort is assessed on a 4-point scale where 0=no discomfort and 3=most discomfort. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Ocular Discomfort on a 4-point Scale
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline2.85 ± 0.921
Change from Baseline at Month 6 (N=37)-1.30 ± 1.266
SecondaryChange From Baseline in Tear Film Break-up Time in the Worse Eye

TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement and a negative number change from baseline indicates a worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Seconds
Change From Baseline in Tear Film Break-up Time in the Worse Eye
SecondsCyclosporine 0.05% Ophthalmic Emulsion
Baseline1.55 ± 0.428
Change from Baseline (N=37)0.92 ± 1.044
SecondaryChange From Baseline in the Interblink Interval in the Worse Eye

The interblink interval measures the time (seconds) between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · Seconds
Change From Baseline in the Interblink Interval in the Worse Eye
SecondsCyclosporine 0.05% Ophthalmic Emulsion
Baseline4.18 ± 3.233
Change from Baseline at Month 6 (N=35)3.04 ± 10.637
SecondaryChange From Baseline in Conjunctival Redness in the Worse Eye

Conjunctival redness is scored in the worse eye on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · Scores on a Scale
Change From Baseline in Conjunctival Redness in the Worse Eye
Scores on a ScaleCyclosporine 0.05% Ophthalmic Emulsion
Baseline2.06 ± 0.709
Change from Baseline at Month 6 (N=37)-0.03 ± 0.707

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclosporine 0.05% Ophthalmic Emulsion—2/40 (5%)12/40 (30%)
Most frequent serious events
Most frequent serious events
EventCyclosporine 0.05% Ophthalmic Emulsion
PneumothoraxRespiratory, thoracic and mediastinal disorders1/40
Renal Failure AcuteRenal and urinary disorders1/40
Transient Ischaemic AttackNervous system disorders1/40
Most frequent other events
Most frequent other events
EventCyclosporine 0.05% Ophthalmic Emulsion
Instillation Site BurnGeneral disorders3/40
Instillation Site PainGeneral disorders3/40
Eye IrritationEye disorders2/40
OsteoarthritisMusculoskeletal and connective tissue disorders2/40
HeadacheNervous system disorders2/40

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cyclosporine 0.05% Ophthalmic Emulsion
Mean59.4 ± 9.05
Sex: Female, Male
Sex: Female, Male(Participants)Cyclosporine 0.05% Ophthalmic Emulsion
Female35
Male5
08

Study locations

1 site
  • Andover, Massachusetts, United States
09

References and documents

Publications

  • Stonecipher KG, Torkildsen GL, Ousler GW 3rd, Morris S, Villanueva L, Hollander DA. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol. 2016 May 13;10:887-95. doi: 10.2147/OPTH.S101627. eCollection 2016. PubMed 27257373 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Sep 2014, 5 months.

Results were first posted in Apr 2016, 1 year 7 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 5 months is below that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2014
First posted
Apr 24, 2014
StartActual
Apr 3, 2014
Primary completionActual
Sep 23, 2014
CompletionActual
Sep 23, 2014
Results first posted
Apr 25, 2016
Last update
Apr 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02121847
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 24, 2014
Start date
Apr 3, 2014
Primary completion
Sep 23, 2014
Completion
Sep 23, 2014
Results posted
Apr 25, 2016
Last update
Apr 18, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion